Stemgent StemAb TRA-1-60 Antibody (Purified), Mouse anti-Human

THIS PRODUCT HAS BEEN DISCONTINUED.  

The TRA-1-60 monoclonal antibody reacts with a pluripotent-stem-cell-specific antigen expressed on undifferentiated human pluripotent stem (PS) cells, embryonal carcinoma (EC) cells, and embryonic germ (EG) cells. The expression of TRA-1-60 on human PS cells is down-regulated upon differentiation.The TRA-1-60 antibody recognizes a neuraminidase-resistant carbohydrate epitope expressed on podocalyxin, a member of the CD34-related family of sialomucins. Podocalyxin is a transmembrane glycoprotein, which has been implicated in the development of aggressiveness in a variety of cancers, including breast and prostate cancer.

Product Name

StemAb TRA-1-60 Antibody (Purified), Mouse anti-Human

Catalog Number

09-0010

Size

100 µL

Formulation

Phosphate-buffered solution, pH 7.2, and 0.09% sodium azide

Storage and Stability

Store at 4 °C protected from light. Do not freeze. Stable for 6 months from date of receipt when stored as directed.

Quality Control

Tested by immunocytochemistry and flow cytometry to ensure product quality.

Notice To Purchaser

Purchaser represents and warrants that it will use StemAb TRA-1-60 Antibody (Purified), Mouse anti-Human purely for research purposes, not for diagnostic use, not for resale, and not for use in humans or veterinary applications. Stemgent will not be held responsible for patent infringement or other violations that may occur with the use of our products.

Recommended Usage

The suggested use of this antibody is a 1:100 dilution for immunocytochemistry and 0.25 µg per 1 × 10⁶ viable cells in 100 µL for flow cytometry. For an application specific protocol, please see Protocol: Immunocytochemistry and Protocol: Immunofluorescence Staining of Cells for Flow Cytometry.

Concentration

0.5mg/mL

Isotype

Mouse IgM

Immunogen

Human embryonal carcinoma cell line 2102Ep

Reactivity

Human

Preparation

This antibody was purified by affinity chromatography.

Clone

TRA-1-60

Specification Sheets

• 09-0010 Specifications Sheet

Safety Data Sheets

• 09-0010 Safety Data Sheet

Protocols

• Protocol: Immunoflourescence Staining of Cells for Flow Cytometry
• Protocol: Immunocytochemistry

1. Takahashi, K., Tanabe K., Ohnuki, M., Narita, M., Ichisaka T., Tomoda K. and Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
2. Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., Slukvin, I.I., and Thomson, J.A. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
3. Schopperle, W.M., and DeWolf, W.C. (2007) The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cells 25: 723-730.
4. Chin, A.C., Fong, W.J., Goh, L.T., Philp, R., Oh, S.K., and Choo, A.B. (2007) Identification of proteins from feeder conditioned medium that support human embryonic stem cells. J Biotechnol. 130: 320-328.
5. Badcock, G., Pigott, C., Goepel, J., and Andrews, P.W. (1999) The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan. Cancer Res. 59: 4715-4719.
6. Andrews, P.W., Goodfellow, P.N., Shevinsky, L., Bronson, D.L., and Knowles, B.B. (1982) Cell surface antigens of a clonal human embryonic carcinoma cell line: morphological and antigenic differentiation in culture. Int. J. Cancer 29: 523-531.

Additional Publications

• Völkner C; Liedtke M; Patters J; Lukas J; Escobar HM; Knuebel G; Bullerdiek J; Holzmann C; Hermann A; Frech MJ. Generation of an iPSC line (AKOSi004-A) from fibroblasts of a female adult NPC1 patient, carrying the compound heterozygous mutation p.Val1023Serfs*15/p.Gly992Arg and of an iPSC line (AKOSi005-A) from a female adult control individual. Stem Cell Res 50:102127 (2021).
• Hamada A; Akagi E; Obayashi F; Yamasaki S; Koizumi K; Ohtaka M; Nishimura K; Nakanishi M; Toratani S; Okamoto T. Induction of Noonan syndrome-specific human-induced pluripotent stem cells under serum-, feeder-, and integration-free conditions. In vitro Cell Devel Biol - Animal :/doi.org/10.1007/s11626-020-00515-9 (2020).
• Völkner C; Liedtke M; Petters J; Huth K; Knuebel G; Escobar HM; Bullerdiek J; Lukas J; Hermann A; Frech MH. Generation of an iPSC line (AKOSi006-A) from fibroblasts of a NPC1 patient, carrying the homozygous mutation p.I1061T (c.3182 T > C) and a control iPSC line (AKOSi007-A) using a non-integrating Sendai virus system. Stem Cell Res 49:102056 (2020).
• Lee S-J; Kim J-H; Wang K-W; Lee B-H; Kim B-S; . Generation of normal induced pluripotent stem cell line KUMCi002-A from bone marrow CD34+ cells of patient with multiple myeloma disease having 13q deletion and IGH translocation. Stem Cell Res 49:102030 (2020).
• Shafa M; Walsh T; Panchalingam KM; Richardson T; Menendez L; Tian X; Babu SS; Dadgar S; Beller J; Yang F; Baghbaderani BA. Long-Term Stability and Differentiation Potential of Cryopreserved cGMP-Compliant Human Induced Pluripotent Stem Cells. Int J Molecular Sci 21:108 (2020).
• Rodríguez-Traver E; Díaz-Guerra E; Rodríguez C; Arenas F; Orera M; Kulisevsky J; Moratalla R; Vicario C. A collection of three integration-free iPSCs derived from old male and female healthy subjects. Stem Cell Res 42:101553 (2020).
• Hamada A; Akagi E; Yamasaki S; Nakatao H; Obayashi F; Ohtaka M; Nishimura K; Nakanishi M; Toratani S; Okamoto T. Induction of integration-free human-induced pluripotent stem cells under serum- and feeder-free conditions. In vitro Cell Dev Biol - Animal :doi.org/10.1007/s11626-019-00412-w (2019).
• Wang X; Han Y; Wang M; Bo C; Zhang Z; Xu L; Liu W; Wang H. Wnt Signaling Protects against Paclitaxel-Induced Spiral Ganglion Neuron Damage in the Mouse Cochlea In Vitro. Biomed Res Intl 2019:7878906 (2019).
• Völkner C; Peter F; Liedtke M; Krohn S; Lindner I; Escobar HM; Cimmaruta C; Lukas J; Hermann A; Frech MJ. Generation of the Niemann-Pick Type C2 patient-derived iPSC line AKOSi001-A. Stem Cell Res in press:17297 (2019).
• Díaz-Fuerra E; Rodríguez-Traver E; Moreno-Jiménez EP; de Rojas I; Rodríguez C; OreraM; Hernández I; Ruiz A; Vicario C. An integration-free iPSC line, ICCSICi007-A, derived from a female Alzheimer's disease patient with the APOE-ε4/ε4 alleles. Stem Cell Research in press :doi.org/10.1016/j.scr.2019.101588 (2019).
• Takahashi M; Yamazaki S. Generation of a human induced pluripotent stem cell line, IMSUTi002-A-1, harboring the leukemia-specific fusion gene ETV6-RUNX1. Stem Cell Research 40: (2019).
• Mura M; Pisano F; Stefanelllo M; Cinevrino M; Boni M; Calabrò F; Crotti L; Valente EM; Schwartz PJ; Brink PA; Gnecchi M. Generation of two human induced pluripotent stem cell (hiPSC) lines from a long QT syndrome South African founder population. Stem Cell Res in Press:https://doi.org/10.1016/j.scr.2019.101510 (2019).
• Mura M; Lee Y-K; Pisano F; Ginevrino M; Boni M; Calabró F; Crotti L; Valente EM; Schwartz PJ; Tse HF; Gnecchi M. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi004-A from a carrier of the KCNQ1-R594Q mutation. Stem Cell Res In press:doi.org/10.1016/j.scr.2019.101431 (2019).
• Hamada A; Akagi E; Obayashi F; Yamasaki S; Koizumi K; Ohtaka M; Nishimura K; Nakanishi M; Toratani S; Okamoto T. Induction of Noonan syndrome-specific human-induced pluripotent stem cells under serum-, feeder-, and integration-free conditions. In vitro Cell Devel Biol - Animal :/doi.org/10.1007/s11626-020-00515-9 (2020).
• Yang G; Hong H; Trres A; Malloy KE; Choudhury CR; Kim J; Daadi MM. Standards for Deriving Nonhuman Primate-Induced Pluripotent Stem Cells, Neural Stem Cells and Dopaminergic Lineage. Int J Mol Sci 19:2788 (2018).
• Baumann H; Jahn M; Muenchau A; Trilck-WInkler M; Lohmann K; Seibler P. Generation and characterization of eight human-derived iPSC lines from affected and unaffected THAP1 mutation carriers. Stem Cell Res 33:60-64 (2018).
• Yucer N; Holzapfel M; Jenkins Vogel T; Lenaeus L; Ornelas L; Laury A; Sareen D; Barrett R; Karlan BY; Svendsen CN. Directed Differentiation of Human Induced Pluripotent Stem Cells into Fallopian Tube Epithelium. Sci Rep 7:10741 (2017).
• Secreto FJ; Li X; Smith AJ; Bruinsma ES; Perales-Clemente E; Oommen S; Hawse G; Hrstka SCL; Arendt BK; Brandt EB; Wigle DA; Nelson TJ. "Quantificaton of etoposide hypersensitivity: A sensitive, functional method for assessing pluripotent stem cell quality."Stem Cells Transl Med 6:18239 (2017)
• Mori E; Fujikura J; Noguchi M; Nakao K; Matsubara M; Sone M; Taura D; Kusakabe T; Evihara K; Tanaka T; Hosada K; Takahashi K; Asaka I; Inagaki N; Nakao K. Impaired adipogenic capacity in induced pluripotent stem cells from lipodystrophic patients with BSCL2 mutations. Metabolism 65:543 (2016)
• Poleganov MA; Eminli S; Beissert T; Herz S; Moon J-I; Goldmann J; Beyer A; Heck R; Burkhart I; Roldan DB; Tureci O; Yi K; Hamilton B; Sahin U. Efficient reprogramming of human fibroblasts and blood-derived endothelial progenitor cells using nonmodified RNA for reprogramming and immune evasion. Human Gene Therapy 26:751 (2015)
• Paull D; Sevilla A; Zhou H; Hahn AK; Kim H; Napolitano C; Tsankov A; Shang L; Krumholz K; Jagaseesan P; Woodard CM; Sun B; Vilboux T; Zimmer M; Forero E; Moroziewicz DN; Martinez H; Malicdan MCV; Weiss KA; Vensand LB; Dusenberry CR; Polus H; Sy KTL; Kahler DJ; Gahl WA; Solomon SL; Chang S; Meissner A; Eggan K; Noggle SA. Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nature Methods 12:885 (2015)
• Yamasaki S; Taguchi Y; Shimamoto A; Mukasa H; Tahara H; Okamoto T. Generation of human induced pluripotent (iPS) cells in serum-and feeder-free defined culture and TGFβ1 regulation of pluripotency. PLoS ONE 9:e87151 (2014)
• Nagy, K., Sung, H-K., Zhang, P., Laflamme, S., Vincent, P, Agha-Mohammadi, S., Woltjen, K., Monetti, C., Michael, I. P., Smith, L. C., Nagy, A. Induced Pluripotent Stem Cell Lines Derive from Equine Fibroblasts. Stem Cell Reviews and Reports 7:693 (2011).